Michael J. Hurley

Michael J. Hurley

Auto-generated profile, based on publicly available information

Michael J. Hurley

Department of Clinical and Movement Neurosciences Aligning Science Across Parkinson's ASAP Collaborative Research Network UCL Queen Square Institute of Neurology London UK

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2013 in Brain
Verified
Journal Article
Open access
PDF file
MHMichael J. Hurley
Michael J. Hurley
BBBianca Brandon
Bianca Brandon
SGSteve M. Gentleman
Steve M. Gentleman
DDDavid T. Dexter
David T. Dexter
In Parkinson’s disease oxidative stress and calcium-induced excitotoxicity have been considered important mechanisms leading to cell death for decades, but the factors that make some neurons vulnerable to neurodegeneration while others remain resistant are not fully understood. Studies of the disorder in animal models suggest that the voltage-gated calcium channel subtype CaV1.3 has a role in making neurons susceptible to neurodegeneration and support earlier work in post-mortem human brain that suggested loss of calcium buffering capacity in neurons correlated with areas of neuronal loss in the substantia nigra of parkinsonian brain. This study examined expression of CaV1 subtypes and the calcium-binding proteins calbindin, calmodulin and calreticulin in areas vulnerable and resistant to neurodegeneration in Parkinson’s disease, in brain from neurologically normal individuals and patients with Parkinson’s disease. In control brain the expression of a specific CaV1 subtype or distribution of each calcium-binding protein did not associate with those regions prone to neurodegeneration in Parkinson’s disease. Whereas, alterations in the amount of both CaV1 subtypes and the calcium-binding proteins were found throughout the brain in Parkinson’s disease. Some changes reflected the cell loss seen in Parkinson’s disease, whereas others represented altered levels of cellular expression, which as they occurred in the absence of cell loss could not be explained as solely compensatory to the neurodegeneration. The finding of increased CaV1.3 subtype expression in the cerebral cortex of early stage Parkinson’s disease, before the appearance of pathological changes, supports the view that disturbed calcium homeostasis is an early feature of Parkinson’s disease and not just a compensatory consequence to the neurodegenerative process. This interpretation is supported further by the finding that the ratio of CaV1 subtypes differed throughout the brain in patients with Parkinson’s disease compared with control subjects, in favour of an increased use of CaV1.3, which would add to the metabolic burden for cells that rely on this CaV1 subtype for electrical activity and could therefore render specific neuronal populations more vulnerable to neurodegeneration.

1 September 2006 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MHM.J. Hurley
M.J. Hurley
PJP. Jenner
P. Jenner

1 November 2003 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
MHM. J. Hurley
M. J. Hurley
DMD. C. Mash
D. C. Mash
PJP. Jenner
P. Jenner

10 November 2003 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
MHMichael J. Hurley
Michael J. Hurley
DMDeborah C. Mash
Deborah C. Mash
PJPeter Jenner
Peter Jenner

23 January 2015 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
RDRobert M. J. Deacon
Robert M. J. Deacon
LGLarry Glass
Larry Glass
MSMike Snape
Mike Snape
MHMichael J. Hurley
Michael J. Hurley
FAFrancisco Altimiras
Francisco Altimiras
PCPatricia Cogram
Patricia Cogram

5 March 2001 in Molecular Brain Research
Verified
Journal Article
Closed access
MHMichael J Hurley
Michael J Hurley
DMDeborah C Mash
Deborah C Mash
PJPeter Jenner
Peter Jenner